JAK2 and nut midline carcinoma: A recent study has reported strong synthetic lethality between RECQL5 and an activating V617F mutation in the JAK2 tyrosine kinase in patients with myeloproliferative neoplasms, and it is possible that the JAK/STAT cascade may be worthy of further exploration in the context of NMC [63].